Risk & Weakness
Pradeep Bonde: 4% Breakout Bearish
7 Findings · last calculated September 18, 2026 Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Market filter active: the list shows 7 hits from US
Methodology & criteria
Bonde's downside counterpart (original Stockbee formula 'c/c1 ≤ 0.96'): a daily loss of at least 4% on above-average volume (relative volume above 1) — a downside momentum burst that often triggers further weak days. Minimum daily volume 100,000 shares, price above $3 (penny-stock filter).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.
🔔 Watch scanner
Hit List
Tip: clicking a column header sorts the table by that column; a second click flips the direction.
| Symbol | Earnings | Avg/Y 3Y | Volatility | Stage | Funda Rating | Piotroski | MktCap | Industry | AI Rating | Deep Dive | Deep-Dive Report | Sector | Price | YTD | 6 Mo. | 1 Year | Off High | Price Target | RS | EPS Rating | ADR 10D | ADR 30D | Beta | P/E | P/E (f) | P/S | P/B | P/FCF | PEG | EV/EBITDA | EBIT Margin | Gross Margin | Net Margin | ROE | ROA | Debt/Eq | Equity Ratio | Sales +/Y | Growth Score | Div. Yield | Payout Ratio | Altman Z | Inst. % | Short % | Analysts |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics Inc | 08/11 | -21 % | ⚠ Wildest 10% 109 % | Stage 2 | D 29 | 3 of 9 | 0.2 $ | Biotechnology | – | — | — | Healthcare | 4.90 $ | +336.8 % | +139.5 % | +279.8 % | −25.6 % | +69.8 % | 98 | 42 | 9.5 % | 9.1 % | -0.99 | — | 0.0 | — | 2.1 | — | — | -2.1 | — | — | 0.0 % | -44.6 % | -30.8 % | — | — | — | 3 | 0.0 % | 0.0 % | 14.5 | 70.5 % | 7.9 % | 2.7 (3) |
| STRZ Starz Entertainment LLC | — | — | 65 % | Stage 2 | E 23 | 4 of 9 | 0.4 $ | Entertainment | – | — | — | Communication Services | 24.80 $ | +143.2 % | +152.5 % | +73.6 % | −9.7 % | +27.5 % | 94 | 50 | 6.8 % | 7.1 % | — | — | 3.6 | 0.3 | — | — | — | 1.4 | — | 54.1 % | -25.1 % | -34.7 % | -0.8 % | — | — | -8.2 % | 5 | 0.0 % | 0.0 % | 1.3 | 92.3 % | 3.9 % | 3.8 (4) |
| CTNM Contineum Therapeutics, Inc. | 08/04 | — | 67 % | Stage 1 | D 43 | 4 of 9 | 0.5 $ | Biotechnology | – | — | — | Healthcare | 13.20 $ | +4.2 % | +18.3 % | +6.6 % | −18.2 % | +69.8 % | 72 | 42 | 9.4 % | 7.3 % | 0.75 | — | 0.0 | — | 1.9 | — | — | 20.8 | — | — | 0.0 % | -26.9 % | -19.2 % | 0.03 | — | -100.0 % | 2 | 0.0 % | 0.0 % | 28.8 | 94.0 % | 7.1 % | 4.6 (5) |
| KRRO Korro Bio, Inc. | 08/11 | -19 % | ⚠ Wildest 10% 181 % | Stage 3 | D 37 | 2 of 9 | 0.2 $ | Biotechnology | – | — | — | Healthcare | 11.80 $ | +71.2 % | +56.9 % | -61.2 % | −78.2 % | +46.4 % | 54 | 42 | 10.9 % | 10.0 % | 2.25 | — | 0.0 | 73.3 | 1.5 | — | — | -5.6 | — | -1,722.3 % | 0.0 % | -87.8 % | -28.0 % | 0.36 | — | +181.5 % | 2 | 0.0 % | 0.0 % | -1.2 | 96.9 % | 11.3 % | 4.6 (10) |
| LMB Limbach Holdings Inc | 08/04 | +88 % | 80 % | Stage 4 | C 51 | 2 of 9 | 0.6 $ | Building Products & Equipment | – | — | — | Industrials | 50.10 $ | +4.6 % | -0.9 % | -51.7 % | −46.8 % | +50.8 % | 23 | 50 | 4.4 % | 6.1 % | 1.41 | — | 12.6 | 0.9 | — | 11.8 | 2.29 | 10.8 | — | 23.6 % | 4.4 % | 18.6 % | 6.8 % | — | — | +24.7 % | 4 | 0.0 % | 0.0 % | 7.5 | 90.5 % | 8.7 % | 4.5 (4) |
| DKNG DraftKings Inc | 08/05 | +0 % | 54 % | Stage 4 | C 52 | 4 of 9 | 11.4 $ | Gambling | – | — | — | Consumer Cyclical | 22.50 $ | -27.0 % | -25.1 % | -47.3 % | −52.6 % | +44.9 % | 15 | 90 | 5.7 % | 5.5 % | 1.63 | 285.0 | 14.8 | 1.8 | 21.0 | 18.5 | 0.06 | 121.0 | 0.4 % | 76.1 % | -2.7 % | 7.9 % | -2.4 % | -1.93 | 14.1 % | +27.0 % | 6 | 0.0 % | 0.0 % | -1.2 | 80.1 % | 7.9 % | 4.5 (32) |
| VEEA Veea Inc. | 08/18 | — | ⚠ Wildest 10% 157 % | Stage 4 | D 36 | 4 of 9 | 0.3 $ | Information Technology Services | – | — | — | Technology | 5.30 $ | -48.2 % | -60.7 % | -50.3 % | −84.5 % | — | 3 | 42 | 16.5 % | 14.0 % | 0.29 | — | 0.0 | 616.0 | — | — | — | 164.5 | — | 74.3 % | 0.0 % | 0.0 % | -40.6 % | — | — | +56.6 % | 1 | 0.0 % | 0.0 % | -25.4 | 3.2 % | 35.7 % | — |
Price Chart
Quarterly Figures
No quarterly data available.
Frequently Asked Questions
Bonde's downside counterpart (original Stockbee formula 'c/c1 ≤ 0.96'): a daily loss of at least 4% on above-average volume (relative volume above 1) — a downside momentum burst that often triggers further weak days. Minimum daily volume 100,000 shares, price above $3 (penny-stock filter).
All scanners are recalculated daily across the entire stock universe — most recently on September 18, 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).
Currently, 7 stocks pass this scanner's criteria (as of September 18, 2026).
Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); fundamentally healthy names (Piotroski ≥ 5 or Fundamental Rating ≥ 55 out of 100) are excluded.
This scanner deliberately hunts for red flags — a hit is a finding, not a recommendation: like a smoke detector that beeps so you look in time. A hit is also not a bankruptcy verdict; most companies save themselves (say, through a capital raise, which dilutes existing shareholders). Portfolio owners use the list as an early-warning system, bargain hunters as an anti-shopping list, experienced traders as a watch list — it is never a buy or short recommendation.
Related scanners
- Altman Z: Distress Zone
- Bankruptcy Study: Stacked Warning Signals
- Below the 50- & 200-SMA
- Beneish M-Score
- Downward Momentum
- Going Concern (Distress Proxy)
- Insolvency Radar: Cash Running Low
- Kathy Donnelly: Liquid Movers Down
- Mike Webster: Overextended (Webby RSI)
- Near 52-Week Low
- Parabolic Death Cross
- Pradeep Bonde: $ Breakout Bearish
- Qullamaggie: Parabolic (Short-Watch)
- RS Weakness (≤10)
- Stage 4 (Downtrend)
- Stan Weinstein: Stage 4
- Stan Weinstein: Stage 4B-
- Thomas Insolvency Candidate
- Weakness Cluster
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.